Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16443930 | 0.92 | HRH4 (0.63) | SCN8AHRH4HRH3SMN1; SMN2CYP1A2 | |
| SCHEMBL8446318 | 0.89 | SCN8A (0.54) | SCN8AHRH4HRH3SMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL8446020 | 0.87 | SCN8A (0.52) | SCN8AHRH4HRH3SMN1; SMN2CYP1A2 | |
| SCHEMBL14420391 | 0.84 | HRH4 (0.56) | SCN8AHRH4HRH3MEN1KMT2A | |
| SCHEMBL14048116 | 0.84 | SCN8A (0.57) | SCN8AHRH4HRH3ALDH1A1CHRM2 | |
| SCHEMBL3233084 | 0.84 | HRH4 (0.59) | HRH4HRH3SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL5044434 | 0.83 | S1PR1 (0.48) | SCN8AHRH4HRH3MEN1KMT2A | |
| SCHEMBL10873793 | 0.82 | SCN8A (0.55) | SCN8AALDH1A1CHRM2RHOCRHOA | |
| SCHEMBL6948873 | 0.82 | RHOC (0.57) | SCN8AHRH4HRH3SMN1; SMN2CYP1A2 | |
| SCHEMBL8350245 | 0.81 | TAAR1 (0.57) | SCN8AALDH1A1CHRM2KCNH2TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177612-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| WO-2019044940-A1 | CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 | 2019-03-07 | — | — | WO | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-7462644-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| CN-1308291-C | Therapeutic agents | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| CN-1753862-A | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| EP-1572626-A1 | THERAPEUTIC AGENTS | Astrazeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050131068-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| WO-2004056748-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131068-A1 | Therapeutic agents | GPR119, INSR, LIPA | SCN8A 2792/4885HRH4 1544/4885HRH3 2149/4885 |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | SCN8A 4528/4885HRH4 3984/4885HRH3 4516/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | SCN8A 2775/4885HRH4 3329/4885HRH3 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.